Spoken Alpha
HRMY
Harmony Biosciences Holdings, Inc.
Overview
Harmony Biosciences Holdings, Inc is a Healthcare company operating in Biotechnology with a $1.94B market cap.
Most recent reported earnings: Q2 FY2026 (Aug 3, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-079 Q&A exchanges
- Q4 FY2025Earnings2026-02-2420 Q&A exchanges
- Q3 FY2025Earnings2025-11-0416 Q&A exchanges
- Q2 FY2025Earnings2025-08-0515 Q&A exchanges
- Q1 FY2025Earnings2025-05-0617 Q&A exchanges
- Q4 FY2024Earnings2025-02-2519 Q&A exchanges
- Q3 FY2024Earnings2024-10-2921 Q&A exchanges
- Q2 FY2024Earnings2024-08-0616 Q&A exchanges
- Q1 FY2024Earnings2024-04-3013 Q&A exchanges
- Q4 FY2023Earnings2024-02-2212 Q&A exchanges
- Q3 FY2023Earnings2023-11-0120 Q&A exchanges
- Q2 FY2023Earnings2023-08-0125 Q&A exchanges
- Q1 FY2023Earnings2023-05-0225 Q&A exchanges
- Q4 FY2022Earnings2023-02-2120 Q&A exchanges
- Q3 FY2022Earnings2022-11-0128 Q&A exchanges
- Q2 FY2022Earnings2022-08-0226 Q&A exchanges
- Q1 FY2022Earnings2022-05-0319 Q&A exchanges
- Q4 FY2021Earnings2022-02-2819 Q&A exchanges
- Q3 FY2021Earnings2021-11-1413 Q&A exchanges
- Q2 FY2021Earnings2021-08-1016 Q&A exchanges
- Q1 FY2021Earnings2021-05-1112 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-03EPS— vs $0.87—Rev— vs ——EODHD
- Q1 FY20262026-05-04EPS$0.79 vs $0.90-12.4%Rev$215.4M vs ——EODHD
- Q4 FY20252026-02-23EPS$0.57 vs $0.86-33.7%Rev$243.8M vs ——EODHD
- Q3 FY20252025-10-26EPS$1.08 vs $0.81+32.5%Rev$239.5M vs ——EODHD
- Q2 FY20252025-08-04EPS$0.68 vs $0.72-5.6%Rev$200.5M vs ——EODHD
- Q1 FY20252025-04-27EPS$0.78 vs $0.91-14.8%Rev$184.7M vs ——EODHD
- Q4 FY20242025-02-19EPS$1.08 vs $0.82+32.2%Rev$201.3M vs ——EODHD
- Q3 FY20242024-10-28EPS$0.79 vs $0.67+17.9%Rev$186.0M vs ——EODHD
- Q2 FY20242024-08-05EPS$0.20 vs $-0.06+100.0%Rev$172.8M vs ——EODHD
- Q1 FY20242024-04-29EPS$0.67 vs $0.60+11.7%Rev$154.6M vs ——EODHD
- Q4 FY20232024-02-21EPS$0.45 vs $0.48-6.3%Rev$168.4M vs ——EODHD
- Q3 FY20232023-10-30EPS$0.75 vs $0.65+15.4%Rev$160.3M vs ——EODHD
- Q2 FY20232023-07-31EPS$0.56 vs $0.63-11.1%Rev$134.2M vs ——EODHD
- Q1 FY20232023-05-01EPS$0.66 vs $0.47+40.4%Rev$119.1M vs ——EODHD
- Q4 FY20222023-02-20EPS$0.79 vs $0.58+36.2%Rev$128.3M vs ——EODHD
- Q3 FY20222022-10-31EPS$1.44 vs $0.13+100.0%Rev$117.2M vs ——EODHD
- Q2 FY20222022-08-01EPS$0.39 vs $0.44-11.4%Rev$107.0M vs ——EODHD
- Q1 FY20222022-05-02EPS$0.51 vs $0.29+75.9%Rev$85.3M vs ——EODHD
- Q4 FY20212022-02-27EPS$0.38 vs $0.36+5.6%Rev$91.2M vs ——EODHD
- Q3 FY20212021-11-08EPS$-0.17 vs $0.29-100.0%Rev$80.7M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-03 | — | $0.87 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-05-04 | $0.79 | $0.90 | -12.4% | $215.4M | — | — | EODHD |
| Q4 FY2025 | 2026-02-23 | $0.57 | $0.86 | -33.7% | $243.8M | — | — | EODHD |
| Q3 FY2025 | 2025-10-26 | $1.08 | $0.81 | +32.5% | $239.5M | — | — | EODHD |
| Q2 FY2025 | 2025-08-04 | $0.68 | $0.72 | -5.6% | $200.5M | — | — | EODHD |
| Q1 FY2025 | 2025-04-27 | $0.78 | $0.91 | -14.8% | $184.7M | — | — | EODHD |
| Q4 FY2024 | 2025-02-19 | $1.08 | $0.82 | +32.2% | $201.3M | — | — | EODHD |
| Q3 FY2024 | 2024-10-28 | $0.79 | $0.67 | +17.9% | $186.0M | — | — | EODHD |
| Q2 FY2024 | 2024-08-05 | $0.20 | $-0.06 | +100.0% | $172.8M | — | — | EODHD |
| Q1 FY2024 | 2024-04-29 | $0.67 | $0.60 | +11.7% | $154.6M | — | — | EODHD |
| Q4 FY2023 | 2024-02-21 | $0.45 | $0.48 | -6.3% | $168.4M | — | — | EODHD |
| Q3 FY2023 | 2023-10-30 | $0.75 | $0.65 | +15.4% | $160.3M | — | — | EODHD |
| Q2 FY2023 | 2023-07-31 | $0.56 | $0.63 | -11.1% | $134.2M | — | — | EODHD |
| Q1 FY2023 | 2023-05-01 | $0.66 | $0.47 | +40.4% | $119.1M | — | — | EODHD |
| Q4 FY2022 | 2023-02-20 | $0.79 | $0.58 | +36.2% | $128.3M | — | — | EODHD |
| Q3 FY2022 | 2022-10-31 | $1.44 | $0.13 | +100.0% | $117.2M | — | — | EODHD |
| Q2 FY2022 | 2022-08-01 | $0.39 | $0.44 | -11.4% | $107.0M | — | — | EODHD |
| Q1 FY2022 | 2022-05-02 | $0.51 | $0.29 | +75.9% | $85.3M | — | — | EODHD |
| Q4 FY2021 | 2022-02-27 | $0.38 | $0.36 | +5.6% | $91.2M | — | — | EODHD |
| Q3 FY2021 | 2021-11-08 | $-0.17 | $0.29 | -100.0% | $80.7M | — | — | EODHD |
Source: EODHD. HRMY reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks HRMY's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.25 | $1.35 | -7.7% | -3.3% | -2.7% |
| Q4 FY2026 | $1.26 | $1.44 | -12.7% | +4.1% | +6.6% |
| Q3 FY2026 | $1.24 | $1.48 | -16.0% | -1.3% | -0.3% |
| Q2 FY2026 | $1.23 | $1.41 | -12.8% | +5.2% | +2.8% |
| Q1 FY2025 | $1.31 | $1.53 | -14.3% | +3.9% | +2.9% |
| Q4 FY2025 | $1.43 | $1.64 | -13.1% | -3.7% | -6.1% |
| Q3 FY2025 | $1.42 | $1.67 | -15.0% | +5.9% | +7.2% |
| Q2 FY2025 | $1.58 | $1.71 | -7.6% | +1.0% | +2.6% |
| Q1 FY2024 | $1.49 | $1.71 | -12.7% | +1.4% | +4.2% |
| Q4 FY2024 | $1.28 | $1.55 | -17.5% | +5.3% | +5.2% |
Guidance change history
Sample- Q1 FY2026Lowered2026-04-15
- Q4 FY2026Lowered2026-13-15
- Q3 FY2026Lowered2026-10-15
- Q2 FY2026Lowered2026-07-15
- Q1 FY2025Lowered2025-04-15
- Q4 FY2025Lowered2025-13-15
- Q3 FY2025Lowered2025-10-15
- Q2 FY2025Lowered2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Jeffrey M DaynoCEO1 yr 5 mo17 callsCurrentSample
CEO since 2025 • 2/4 beats (50%) • last call held guidance Q2 FY2026
- Sandip A KapadiaCFO1 yr 5 mo20 callsCurrentSample
CFO since 2025 • 3/4 beats (75%) • last call held guidance Q1 FY2026
- Peter AnastasiouCOO2 mo1 callCurrentSample
COO since 2026 • 1/2 beats (50%) • guidance suspended Q2 FY2026
- Adam H ZaeskeCHIEF COMMERCIAL OFFICER1 yr 2 mo5 callsCurrentSample
OTHER_C_SUITE since 2025 • 3/4 beats (75%) • last guidance raise Q1 FY2026
- Andrew SerafinCHIEF STRATEGY OFFICER1 yr 5 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 2/4 beats (50%) • last guidance raise Q2 FY2026
- Kumar BudurCHIEF MEDICAL OFFICER1 yr 5 mo11 callsCurrentSample
OTHER_C_SUITE since 2025 • 2/4 beats (50%) • last guidance raise Q1 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for HRMY.
$ curl https://api.spokenalpha.com/v1/companies/HRMYFAQ
Frequently asked about HRMY
Where can I find Harmony Biosciences Holdings, Inc.'s (HRMY) earnings call transcripts?
Spoken Alpha indexes HRMY's earnings call transcripts at https://spokenalpha.com/companies/HRMY. Each call links to attributed speakers and parsed analyst Q&A. Harmony Biosciences Holdings, Inc.'s own investor relations page is at https://ir.harmonybiosciences.com/.
When was Harmony Biosciences Holdings, Inc.'s most recent earnings call?
Harmony Biosciences Holdings, Inc. (HRMY) held its most recent earnings call on 2026-05-07, covering fiscal Q1 2026.
What sector is HRMY in?
Harmony Biosciences Holdings, Inc. (HRMY) operates in the Healthcare sector (Biotechnology industry).